Real Patient Stories
Real stories of migraine-free days with Emgality1
Hear from real patients with episodic migraine (4-14 migraine headache days [MHDs] per month)1a
View efficacy results in patients with episodic migraine
aPatients were compensated for their time.
Lisa, a traveler with migraine
Lisa has had episodic migraine for over 33 years.
Bonnie, a food enthusiast with migraine
Bonnie has had episodic migraine for nearly 15 years.
SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
Real stories of migraine-free days with Emgality1
Hear from real patients with chronic migraine (≥15 headache days per month)1a
View efficacy results in patients with chronic migraine
aPatients were compensated for their time.
Leia, a parent with migraine
Leia has had chronic migraine for over 26 years.
Ashley, a fiancée with migraine
Ashley has had chronic migraine for almost 15 years.
Hear from a real patient with episodic cluster headache1a
aPatients were compensated for their time.
Bryan, a football enthusiast
Bryan has experienced up to 35 attacks per week during an active cluster period.
SELECT IMPORTANT SAFETY INFORMATION
Adverse Reactions
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.
Learn how Emgality works
Episodic cluster headache
Discover the efficacy of Emgality for patients with migraine or episodic cluster headache
SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
Watch how to use the Emgality Pen or Prefilled Syringe
The Emgality Pen
The Emgality Prefilled Syringe
Instructions for Use–100 mg syringe for episodic cluster headache
If you or your patients have any questions about Emgality, call 1-833-EMGALITY (1-833-364-2548) to talk to a healthcare provider.
SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.
Start your patients on Emgality today. View savings carda and additional resources
aGovernmental beneficiaries excluded; terms and conditions apply.
Reference: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.